One Year Later, Groups Press Sebelius To Backtrack On OTC Plan B Block
This article was originally published in The Tan Sheet
Executive Summary
The Reproductive Health Technologies Project, plus 45 other organizations and 18 professionals, urge HHS Secretary Kathleen Sebelius to revisit her decision to overrule full OTC availability of Teva’s Plan B One-Step emergency contraceptive.
You may also be interested in...
FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives
In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.
FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives
In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.
FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives
In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.